Nkarta Inc (NKTX)vsBeiGene, Ltd. (ONC)
NKTX
Nkarta Inc
$2.75
+4.56%
HEALTHCARE · Cap: $190.52M
ONC
BeiGene, Ltd.
$372.49
-0.88%
HEALTHCARE · Cap: $42.08B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1591938342% more annual revenue ($6.13B vs $385). ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 62/100 (C+).
NKTX
Avoid32
out of 100
Grade: F
ONC
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NKTX.
Margin of Safety
+80.2%
Fair Value
$1776.44
Current Price
$372.49
$1403.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.1x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NKTX
The strongest argument for NKTX centers on Price/Book, Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum. PEG of 1.07 suggests the stock is reasonably priced for its growth.
Bear Case : NKTX
The primary concerns for NKTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 66.7x leaves little room for execution misses.
Key Dynamics to Monitor
NKTX profiles as a value stock while ONC is a growth play — different risk/reward profiles.
NKTX carries more volatility with a beta of 0.94 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (62/100 vs 32/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nkarta Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?